• Patients included in this study must meet all of the following criteria:

‣ Aged 18 or above;

⁃ Histologically or cytologically confirmed locally advanced inoperable (such as T4b, or N2-3) or metastatic urothelial carcinoma, including bladder, ureter, renal pelvis and urethra;

⁃ Patients who have received previous treatment with immune checkpoint inhibitors (PD-1/PD-L1 monoclonal antibodies) are allowed;

⁃ According to RECIST1.1 standard, there is at least one measurable target lesion;

⁃ ECOG score ≤2;

⁃ Good bone marrow, kidney (serum creatinine clearance calculated by CG formula\> 30 mL/min), liver and coagulation function:

⁃ Expected survival period ≥ 6 months;

⁃ The patient understands the research procedures and signs the informed consent form in writing to indicate his/her agreement to participate in the study;

⁃ Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 7 days before the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required.

‣ If there is a risk of pregnancy, male and female patients should use highly effective contraception (i.e., a method with a failure rate of less than 1% per year) and continue for at least 180 days after stopping the trial treatment.